Top 5 Biotechnology Startup Investors in Isle of Man (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Foresite Capital
VC Fund
|
2 | United States, United Kingdom, China | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $17M–$270M |
|
Jim Mellon
Angel
|
1 | United States, United Kingdom, Israel | Series A, Seed | Biotechnology, Food and Beverage, Food Processing | $894k–$47M |
|
Juvenescence
VC Fund
|
1 | United States, Hong Kong, Isle of Man | Venture - Series Unknown, Series A, Seed | Biotechnology, Pharmaceutical, Health Care | $1.5M–$19M |
|
Andrew Banks
Angel
|
1 | Isle of Man | Seed | Biopharma, Biotechnology, Pharmaceutical | |
|
Greg Bailey
Angel
|
1 | United States, Isle of Man | Series A, Post-IPO Equity, Seed | Biotechnology, Pharmaceutical, Health Care | $3M–$80M |
| Access all 15 investors in Isle of Man Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Investor list
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 225
- Round size: Series A $17M–$165M; Series B $24M–$140M; Series C $37M–$270M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $900M in 2024
Portfolio highlights
- Thyme Care — Thyme Care is a dedicated team of nurses and care experts offering value-based cancer care to help you through all phases of the cancer experience.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Food Processing
- Stage:Series A, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 35
- Round size: Seed $894k–$20M; Series A $3M–$47M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Callers AI — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
- Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
- The Duppy Share — The Duppy Share is a new Caribbean “quirky” golden rum from the islands of Barbados and Jamaica.
We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Venture - Series Unknown, Series A, Seed
- Geography: United States, Hong Kong, Isle of Man
Investor stats
- Total investments: 17
- Round size: Series A $3M–$19M; Venture - Series Unknown $1.5M–$10M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- LyGenesis — LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
- Morphoceuticals — Reprogramming the Software of Life: Understanding the bioelectric network that controls tissue repair and organ regeneration
- MDI Therapeutics — MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers.
Andrew Banks - Chairman and Co-Founder @ ABRY Partners
Show more...Investment focus
- Industry: Biopharma, Biotechnology, Pharmaceutical
- Stage:Seed
- Geography: Isle of Man
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director andco-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Series A, Post-IPO Equity, Seed
- Geography: United States, Isle of Man
Investor stats
- Total investments: 10
- Round size: Series A $3M–$19M; Post-IPO Equity $15M–$80M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
- Serina Therapeutics — Serina Therapeutics is a biotech company focused on polymer technology to improve how small molecule therapeutics behave in the body
- Bristol-Myers Squibb — Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
Biotechnology Investor funding in Isle of Man at a glance
Stats across 7 deals from 15 investors.
Access all 15 investors in Isle of Man Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in Isle of Man investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 15 investors investing in Isle of Man Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Sign up with Google
Sign up with LinkedIn
